Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes

At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.

Branded graphic with the text “Patient Engagement, Designed to Last”

The Reverba Global team made valuable connections at the 13th Annual Patients as Partners in Clinical Research Conference, focused on raising the patient voice in R&D to drive better clinical outcomes for all. In addition, CEO Cheryl Lubbert shared her expertise on a panel, discussing how to protect patient engagement through organizational change.

Cheryl shared several key takeaways from the panel.

Reorganizations can expose stronger systems needed in patient engagement models

When engagement is dependent on individuals, informal processes, or fragmented systems, disruption is inevitable. Not because teams don’t care, but because the program was never designed to carry engagement through change.

During periods of change, the cracks in that system become more visible. Ownership becomes unclear, follow-up pathways break down, and sites—facing competing demands—deprioritize engagement. Fixing this isn’t about reminding teams to communicate better. It requires intentional system design.

The organizations that are getting this right are doing something fundamentally different:
they are treating patient engagement as operational infrastructure, not an initiative.

What does that look like?

  • A persistent patient relationship layer, so patients aren’t tied to a study or a person
  • A shared system of record, so context and history don’t get lost
  • Standardized engagement pathways, so communication doesn’t restart every time ownership shifts
  • Clear cross-functional ownership that doesn’t disappear in a reorganization

Engagement continuity that survives change is designed upfront

One of the clearest themes across pharma, CROs, and solution partners was that resilience is not something you add later; it’s something you design from the start. That shows up in very specific ways:

  • Standardization early in the lifecycle
    IRB- and EC-approved templates, predefined communication pathways, and consistent engagement frameworks ensure that programs don’t need to be rebuilt when teams shift.
  • Embedded governance across functions
    Engagement isn’t owned by a single team. Instead, it is integrated across medical, clinical, and patient functions, with clear accountability that persists even when reporting lines change.
  • Institutional memory that outlasts individuals
    Whether through centralized hubs or repeatable processes, the knowledge that drives engagement must be preserved beyond any one team.

Building trust requires automation and the human touch

“I never heard back” remains one of the most common—and most damaging—patient experiences.

This is both a communication issue and a systems failure. Structured engagement initiatives can help ensure every patient gets they attention they deserve.

  • Automated journeys that maintain cadence and ensure no patient is left without follow-up
  • Clear escalation pathways when expected responses don’t occur
  • Alternative engagement channels, such as community hubs, for those who fall out of primary pathways

But just as important is what cannot be automated. Nurse-led engagement, human check-ins, and empathetic, scientifically rigorous communication remain essential, especially in moments of uncertainty or transition. These are the touchpoints that reinforce trust when systems alone aren’t enough.

The organizations that succeed here aren’t choosing between efficiency and empathy.
They are designing for both, ensuring consistency through systems and trust through human connection.

Continuity isn’t a courtesy, it’s an obligation

Another critical shift discussed on the panel is how organizations think about the end of a program. Trial closures, pauses, and acquisitions are often treated as operational endpoints.

For patients, they are anything but.

Without defined continuity models, communication stops abruptly. Relationships disappear without explanation, and patients are left without closure or direction.

What leading organizations are doing instead is operationalizing continuity:

  • Predefined wind-down protocols that are built into startup planning, not created reactively
  • Minimum resourcing models that ensure engagement continues even as programs close
  • Sustained relationship networks that extend beyond individual studies or sponsors

This reframes engagement from a program-based activity to a longitudinal relationship model.

In conclusion

Patient engagement cannot depend on stability within the organization, because stability is no longer the norm. It must be built to function through instability.

That requires a shift:

  • From programs to systems
  • From individuals to infrastructure
  • From activity to accountability
  • From short-term execution to long-term continuity

Because from the patient’s perspective, none of the internal complexity matters. What matters is whether the experience is consistent, responsive, and trustworthy, no matter what is happening behind the scenes. And that is not something that can be improvised. It has to be built.


The Latest

  • Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes
    Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes

    At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.

  • Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
    Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?

    AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…

  • Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact
    Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact

    Late-stage clinical programs establish the evidence required for regulatory evaluation, but they do not guarantee adoption, access, or commercial performance. Translating that evidence into real-world impact requires patient-centered execution and…